Soros Capital Management LLC Makes New $5.16 Million Investment in Intuitive Surgical, Inc. (NASDAQ:ISRG)

Soros Capital Management LLC bought a new position in Intuitive Surgical, Inc. (NASDAQ:ISRG - Free Report) during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund bought 10,500 shares of the medical equipment provider's stock, valued at approximately $5,158,000. Intuitive Surgical comprises about 1.2% of Soros Capital Management LLC's portfolio, making the stock its 26th biggest position.

Other institutional investors and hedge funds have also modified their holdings of the company. FMR LLC increased its holdings in Intuitive Surgical by 8.3% in the 3rd quarter. FMR LLC now owns 10,971,085 shares of the medical equipment provider's stock valued at $5,389,765,000 after buying an additional 838,793 shares during the period. Fisher Asset Management LLC increased its position in Intuitive Surgical by 1.8% in the third quarter. Fisher Asset Management LLC now owns 4,782,381 shares of the medical equipment provider's stock worth $2,349,441,000 after purchasing an additional 86,208 shares during the period. Baillie Gifford & Co. boosted its stake in Intuitive Surgical by 0.6% in the third quarter. Baillie Gifford & Co. now owns 3,848,547 shares of the medical equipment provider's stock valued at $1,890,676,000 after acquiring an additional 24,183 shares during the last quarter. American Century Companies Inc. increased its holdings in Intuitive Surgical by 3.0% in the second quarter. American Century Companies Inc. now owns 2,398,193 shares of the medical equipment provider's stock valued at $1,066,837,000 after purchasing an additional 70,556 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. grew its holdings in Intuitive Surgical by 1.3% during the third quarter. Charles Schwab Investment Management Inc. now owns 2,227,467 shares of the medical equipment provider's stock valued at $1,094,288,000 after purchasing an additional 28,703 shares during the period. Hedge funds and other institutional investors own 83.64% of the company's stock.

Intuitive Surgical Trading Down 0.5 %

ISRG traded down $2.60 during midday trading on Wednesday, hitting $539.50. 551,053 shares of the company traded hands, compared to its average volume of 1,453,664. The business has a 50 day simple moving average of $506.81 and a two-hundred day simple moving average of $466.29. The company has a market capitalization of $192.16 billion, a price-to-earnings ratio of 87.15, a PEG ratio of 5.28 and a beta of 1.39. Intuitive Surgical, Inc. has a 52-week low of $304.50 and a 52-week high of $552.00.

Intuitive Surgical (NASDAQ:ISRG - Get Free Report) last released its quarterly earnings data on Thursday, October 17th. The medical equipment provider reported $1.56 EPS for the quarter, beating analysts' consensus estimates of $1.24 by $0.32. Intuitive Surgical had a return on equity of 13.41% and a net margin of 28.51%. The firm had revenue of $2.04 billion for the quarter, compared to analysts' expectations of $2.01 billion. Equities research analysts anticipate that Intuitive Surgical, Inc. will post 5.45 earnings per share for the current year.

Insiders Place Their Bets

In other Intuitive Surgical news, CEO Gary S. Guthart sold 18,151 shares of the stock in a transaction that occurred on Wednesday, October 30th. The shares were sold at an average price of $511.63, for a total value of $9,286,596.13. Following the completion of the sale, the chief executive officer now owns 24,219 shares of the company's stock, valued at $12,391,166.97. This trade represents a 42.84 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Jamie Samath sold 108 shares of the stock in a transaction that occurred on Tuesday, November 26th. The shares were sold at an average price of $542.06, for a total value of $58,542.48. Following the transaction, the chief financial officer now owns 8,757 shares of the company's stock, valued at approximately $4,746,819.42. This trade represents a 1.22 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 50,647 shares of company stock worth $26,170,907. 0.80% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

A number of analysts have recently commented on the stock. Redburn Atlantic raised shares of Intuitive Surgical from a "neutral" rating to a "buy" rating and boosted their price objective for the stock from $380.00 to $510.00 in a research report on Friday, August 2nd. Piper Sandler restated an "overweight" rating and issued a $538.00 target price (up previously from $495.00) on shares of Intuitive Surgical in a research report on Friday, October 18th. Erste Group Bank upgraded shares of Intuitive Surgical from a "hold" rating to a "buy" rating in a report on Tuesday, November 19th. BTIG Research lifted their price objective on shares of Intuitive Surgical from $535.00 to $561.00 and gave the stock a "buy" rating in a report on Tuesday. Finally, Raymond James increased their target price on shares of Intuitive Surgical from $500.00 to $540.00 and gave the stock an "outperform" rating in a research report on Monday, October 14th. One analyst has rated the stock with a sell rating, five have issued a hold rating and fourteen have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $526.06.

Intuitive Surgical Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.